Search Results
Your search for ASCO matches 21586 pages
Showing 19051 - 19100Rare-Cancer Expert Richard Carvajal, MD, Appointed Director of Experimental Therapeutics
Richard D. Carvajal, MD, has been named Director of the Experimental Therapeutics/Phase I program and melanoma service in medical oncology at New York-Presbyterian/Columbia University Medical Center effective November 1, 2014. Dr. Carvajal, a medical oncologist, has extensive clinical expertise in...
FDA Drug Approvals 2014
Nivolumab (Opdivo), a monoclonal antibody, was approved for treatment of metastatic melanoma. Approved December 22, 2014. Olaparib (Lynparza), a poly (ADP-ribose) polymerase (PARP) inhibitor, was approved for treatment of BRCA-mutated advanced ovarian cancer. Approved December 19, 2014....
Oncologists, Pathologists Partner to Improve Practice and Optimize Patient Care
The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) have announced a new partnership to optimize patient care and foster excellence in the practices of pathology and oncology through interprofessional education, advocacy, quality improvement,...
FDA’s Janet Woodcock, MD, Receives Lifetime Achievement Award From the Institute for Safe Medication Practices
Janet Woodcock, MD, Director of the U.S. Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research, has been awarded the Institute for Safe Medication Practices Lifetime Achievement Award, which recognizes “an individual who has had a significant career history of making...
ASCO and AACR Call for Regulation of E-Cigarettes and Other Electronic Nicotine Delivery Systems
The American Association for Cancer Research (AACR) and ASCO have outlined steps in a joint statement to guide policymakers as they work to minimize the potential negative consequences of electronic cigarettes (e-cigarettes) and other electronic nicotine delivery systems without undermining their...
Colorectal Cancer 2015
Despite advances in detection and treatment, colorectal cancer remains the third deadliest cancer among men and women in the United States. To get a better understanding of the current state of this disease and what lies ahead, The ASCO Post recently spoke with colorectal cancer expert John L....
Molecular Pathologists vs the FDA: Proposed Regulation of Laboratory-Developed Tests Sparks Debate
The packed ballroom looked like a plenary session at any big medical research meeting. But on the dais were representatives of the Food and Drug Administration (FDA), the subject was the Agency’s proposed regulation of laboratory-developed tests, and the attendees who lined up to ask questions for...
Overdiagnosis May Be Overblown in Lung Cancer Screening
“Overdiagnosis has been overblown” in concerns voiced about lung cancer screening with low-dose computed tomography, Andrea B. McKee, MD, told participants at the opening session of the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. Dr. McKee is Chair of the Department of Radiation ...
More Than 1.5 Million Cancer Deaths Averted During 2 Decades of Dropping Mortality
The American Cancer Society’s annual cancer statistics report found that a 22% drop in cancer mortality over 2 decades led to the avoidance of more than 1.5 million cancer deaths that would have occurred if peak rates had persisted. And while cancer death rates have declined in every state, the...
Vitamin D Protects Against Colorectal Cancer by Boosting the Immune System
A study by investigators at Dana-Farber Cancer Institute has demonstrated that vitamin D can protect some people with colorectal cancer by heightening the immune system’s vigilance against tumor cells. The research, released earlier this month by the journal Gut, shows a link between vitamin D and...
FDA Approves Olaparib to Treat BRCA-Mutated Advanced Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to olaparib (Lynparza) for women with advanced ovarian cancer with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, as detected by an FDA-approved test, who have been treated with three...
FDA Approves Ramucirumab Combination for Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved ramucirumab (Cyramza) for use in combination with docetaxel for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK mutations ...
FDA Approves Nivolumab for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, is intended for patients who have been...
Expert Point of View: Mary L. Disis, MD
Study discussant Mary L. Disis, MD, Professor of Medicine and Associate Dean of Translational Science at the University of Washington, Seattle, commented that the response rate, approaching 20%, is “in the ballpark” of those observed in melanoma, lung cancer, and renal cancer. She pointed out that...
Expert Point of View: Fredrick Hagemeister, MD
As session moderator, Fredrick Hagemeister, MD, Professor of Medicine, University of Texas MD Anderson Cancer Center, Houston, commented during the discussion of Dr. Connors’ study. He first emphasized the need to establish the safety of new drugs in clinical trials before incorporating them...
Ovarian Suppression Plus Hormonal Therapy May Be Practice-Changing in Premenopausal Hormone Receptor–Positive Early-Stage Breast Cancer
Results of the large International Breast Cancer Study Group (IBCSG)-coordinated SOFT trial present a convincing argument for the addition of ovarian function suppression to adjuvant hormonal therapy to reduce the risk of tumor recurrence in younger women with hormone receptor–positive early-stage...
What Is a Physician? Call a Spade a Spade
Anyone who has awoken from a decades-long amnestic spell can be forgiven for thinking that physicians cannot do anything right nowadays. Compared with decades ago, when physicians did mostly right, we now seem to be nowhere close to correctness. Nearly every malady that befalls the health-care...
Unraveling the Mysteries of Epithelioid Hemangioendothelioma
Epithelioid hemangioendothelioma is a rare and devastating vascular sarcoma that affects between 100 and 200 people, mostly young adults, each year in the United States. The cancer may arise as a solitary lesion but more commonly presents with metastatic involvement, usually in the liver and lungs. ...
Patients May Voice Concerns About Chemotherapy Effects on the Brain Even If They Have Never Heard of ‘Chemobrain’
The concept of “chemobrain” is underrecognized, noted Serena Wong, MD, co-investigator of a clinical trial examining the effects of chemotherapy and hormonal therapy on the brain. Dr. Wong is a medical oncologist at Rutgers Cancer Institute of New Jersey and Assistant Professor of Medicine at...
'Chemobrain’ Study Aims to Correlate Structural Changes Within the Brain and Psychomotor Function
The novelty of our approach is that we are going to be using multiple modalities” to study the effects of chemotherapy and hormonal therapy on the brain, looking for structural changes within the brain and how these changes might affect psychomotor function, particularly upper-extremity movements...
Loretta Doan, PhD, Named Vice President of Policy and Global Affairs at AACC
The American Association of Clinical Chemistry (AACC) has announced that Loretta L. Doan, PhD, has assumed the position of Vice President of Policy and Global Affairs. Prior to joining AACC, Dr. Doan served as Director of Science Policy at the Endocrine Society, an organization representing more...
Elizabeth M. Jaffee, MD, Named Deputy Director of Johns Hopkins Kimmel Cancer Center
Elizabeth M. Jaffee, MD, a pioneer in the field of vaccine therapy for pancreatic cancer and leader in immunology research, has been appointed Deputy Director of the Johns Hopkins Kimmel Cancer Center. Dr. Jaffee, the Dana and Albert “Cubby” Broccoli Professor of Oncology at the Johns Hopkins...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
2015 Oncology Meetings
FEBRUARY AACR-SNMMI Joint Conference: State-of-the-Art Molecular Imaging in Cancer Biology and TherapyFebruary 11-14 • San Diego, California For more information: www.aacr.org 2015 BMT Tandem Meeting American Society for Blood and Marrow TransplantationFebruary 11 - 15 • San Diego, California For...
Suzanne Topalian, MD, Recognized for Pioneering Work in Immunotherapy Treatment of Melanoma and Other Cancers
The Melanoma Research Alliance has reported that Suzanne Topalian, MD, Chair of the group’s Scientific Advisory Panel, and former Chief Scientific Officer, has been named one of 10 people in science who mattered in 2014 by the Nature International Weekly Journal of Science. Dr. Topalian was cited...
West Cancer Center Announces The University of Tennessee/West Institute for Cancer Research
West Cancer Center has announced the establishment of The University of Tennessee (UT)/West Institute for Cancer Research, a nonprofit public charity fully dedicated to raising funds for adult cancer research in Memphis. The UT/West Institute for Cancer Research is soliciting grants from government ...
Friends of Cancer Research Holds Annual Conference on Clinical Cancer Research
Friends of Cancer Research, in conjunction with the Engelberg Center for Health Care Reform at Brookings, recently held the seventh annual Conference on Clinical Cancer Research in Washington, DC. The panels that comprised the daylong meeting discussed a future that has already begun. The most...
Transitioning From Volume to Value in Cancer Care
In an oncology health-care system that is increasingly changing its delivery and payment models, how do busy oncologists successfully bridge the transition from a volume- to value-based, patient-centric model? This, and other topics on value fueled a robust discussion at the Association of...
Supplemental New Drug Application for Carfilzomib
Amgen and its subsidiary Onyx Pharmaceuticals, Inc, announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) carfilzomib (Kyprolis) to seek approval for the treatment of patients with relapsed multiple myeloma who have received at least...
CPX-351 Receives Fast Track Designation for Secondary Acute Myeloid Leukemia in Elderly Patients
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Celator Pharmaceuticals’ investigational agent CPX-351, a liposomal formulation of cytarabine:daunorubicin, for the treatment of elderly patients with secondary acute myeloid leukemia. The FDA established the Fast...
New Choosing Wisely List, Leukemia Quick-Takes From ASH
Nearly 5,000 scientific abstracts were presented at the 2014 American Society of Hematology (ASH) Annual Meeting and Exhibition in San Francisco. Along with our targeted coverage of the meeting’s key newsmakers, The ASCO Post provides you with these brief reports of other interesting...
Moffitt Cancer Center Reports on Faculty Participants in International Discovery of Genetic Risk Factors for Ovarian Cancer
Researchers from Moffitt Cancer Center in Tampa, Florida have participated in a global effort that has identified six new regions of the genome that increase risk of epithelial ovarian cancer, according to a news release from Moffitt. The collaborative study was published recently in Nature...
Expert Point of View: Matthew J. Ellis, MB, BChir, PhD
Matthew J. Ellis, MB, BChir, PhD, Director of the Lester and Sue Smith Breast Center at Baylor College of Medicine, Houston, commented on endocrine resistance and the potential of the four-gene panel for assessing resistance for The ASCO Post. Endocrine response and resistance is a research focus...
ASCO Policy Statement Urges Removal of Barriers to Patient Participation in Phase I Clinical Trials
ASCO has released a policy statement calling for greater access to and education about phase I clinical trials, the first-in-human studies of new agents designed to fight cancer. In “The Critical Role of Phase I Trials in Cancer Research and Treatment” ASCO policy statement, the Society stresses...
Help Your Patients Understand the Importance of Phase I Clinical Trials
Encourage your patients to consider participating in clinical trials, including phase I clinical trials. Direct your patients to www.cancer.net/clinicaltrials for detailed information about the purpose and advantages of clinical trials and why today’s phase I studies are different. On the...
ASCO Names Advance of the Year, Reviews Top Research Trends
In just a year’s time, four new therapies have been approved for patients with chronic lymphocytic leukemia (CLL), treatments that are highly effective and far easier for patients to tolerate. These therapies are a major step forward, bringing renewed hope to nearly 120,000 people living with CLL...
Five Organizations Awarded 2015 International Innovation Grants to Improve Cancer Care in Low- and Middle-Income Countries
The Conquer Cancer Foundation of ASCO has announced the five recipients of the 2015 International Innovation Grant. This grant supports novel and innovative projects that may improve diagnosis, prevention, and treatment of cancer in low- and middle-income countries. For 2015, the 1-year grants of...
Cornerstone Spotlight: Frank M. Muller, Jr
Frank M. Muller, Jr, the newest member of the Conquer Cancer Foundation (CCF) Cornerstone Planned Giving Society, has a 40-year history of successfully leading investment and high-tech corporations. He served 8 years on active duty in tours to Vietnam. It is rare for him to experience a challenge...
Molecular Classification Predicts Postcystectomy Recurrence in High-Risk Bladder Cancer
Radical cystectomy is the standard therapeutic option for patients with muscle-invasive bladder cancer. However, 5-year overall survival for high-risk patients with pT3, pT4, pN-negative, and pN-positive M0 bladder cancer after radical cystectomy is only about 50% and ranges from 32% in patients...
University of Pittsburgh Appoints Director of Stem Cell Transplantation
Warren Shlomchik, MD, has been named Director of Stem Cell Transplantation and Cell Therapies for the University of Pittsburgh’s Division of Hematology-Oncology and the University of Pittsburgh Cancer Institute (UPCI). His appointment is effective March 1, 2015. He also will serve as UPCI’s...
Treating Bladder Cancer in 2015
Treatment of advanced bladder cancer continues to prove challenging, and therapies that offer long-term survival remain elusive. The ASCO Post recently spoke with Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, President of the Levine Cancer Center, Charlotte, North Carolina, about the current state...
FDA Appoints Robert Califf, MD, Deputy Commissioner for Medical Products and Tobacco
U.S. Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg, MD, has appointed Robert Califf, MD, as the FDA Deputy Commissioner for Medical Products and Tobacco. Dr. Califf is a leader in cardiology, clinical research, and medical economics, who is currently serving as Vice...
FDA Expands Approved Use of Ibrutinib for Waldenström’s Macroglobulinemia
The U.S. Food and Drug Administration (FDA) today expanded the approved use of ibrutinib (Imbruvica) for patients with Waldenström’s macroglobulinemia, a rare, indolent type of B-cell lymphoma. Ibrutinib is the first therapy indicated specifically for Waldenström’s macroglobulinemia and previously...
Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy: A Winner in Older Patients With Leukemia
Inotuzumab ozogamicin combined with a low-intensity chemotherapy called mini-hyper-CVD achieved highly encouraging results in older patients with acute lymphoblastic leukemia (ALL) in a phase II study reported at the 56th Annual Meeting of the American Society of Hematology.1 After the...
Expert Point of View: Ann H. Partridge, MD, MPH
Ann H. Partridge, MD, MPH, Associate Professor of Medicine at Harvard Medical School, commented on this study to The ASCO Post: With taxanes after doxorubicin/cyclophosphamide (AC), it’s “dealer’s choice.” However, she noted that most oncologists do not give every-3-week paclitaxel now. “Many have...
ASCO Releases Annual Report on Progress Against Cancer
ASCO recently released its report, Clinical Cancer Advances 2015: An Annual Report on Progress Against Cancer, and for the first time announced its cancer Advance of the Year: gains made in the treatment of chronic lymphocytic leukemia (CLL). The report credited improvements in CLL care with four...
Cancer Genetics: Looking Back, Looking Ahead
At the 2014 San Antonio Breast Cancer Symposium, The ASCO Post sat down with geneticist Mary-Claire King, PhD, for some personal musings about her career and how she might guide young researchers who want to follow in her footsteps. Dr. King is known for a variety of accomplishments in genetics,...
Expert Point of View: George J. Chang, MD
George J. Chang, MD, Chief of Colon and Rectal Surgery and Director of Clinical Operations, Minimally Invasive and New Technologies in Oncologic Surgery Program at The University of Texas MD Anderson Cancer Center, Houston, shared his insights on the study by Dr. Smith and colleagues with The ASCO...
Dr. Howard Fine Named Founding Director of the Brain Tumor Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center
Howard A. Fine, MD, has been appointed to lead the newly established neuro-oncology program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, effective February 2. He will serve as Director of the Brain Tumor Center and Associate Director for Translational Research in the Sandra and...
Glioblastoma Clinical Trials
I am writing in regard to the recent installment to “Clinical Trials” on Glioblastoma published in The ASCO Post (February 10, 2015, pages 69-71). As a principal investigator, I’d also like to call attention to the following glioblastoma trial, which remains open. PHASE II Study Type: Phase...
